Head to Head Analysis: NeurAxis (NASDAQ:NRXS) vs. Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Cytosorbents and NeurAxis”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytosorbents $37.06 million 0.35 -$8.20 million ($5.38) -0.77
NeurAxis $6.53 million 6.88 -$14.63 million ($1.06) -3.98

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 21.1% of NeurAxis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Cytosorbents and NeurAxis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents 1 0 2 0 2.33
NeurAxis 0 1 1 0 2.50

Cytosorbents presently has a consensus target price of $104.75, indicating a potential upside of 2,418.03%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 208.06%. Given Cytosorbents’ higher possible upside, equities research analysts plainly believe Cytosorbents is more favorable than NeurAxis.

Volatility and Risk

Cytosorbents has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Profitability

This table compares Cytosorbents and NeurAxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytosorbents -45.06% -689.23% -41.26%
NeurAxis -492.76% N/A -641.25%

Summary

Cytosorbents beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About Cytosorbents

(Get Free Report)

Cytosorbents Corp. develops blood-purification technologies for use in hospitals and other clinical settings. Its products are designed to work with extracorporeal circuits, where blood is circulated outside the body and passed through a purification device. The company’s best-known product, CytoSorb, is an adsorber intended to remove certain inflammatory substances and other compounds from blood. It is used in areas such as critical care and cardiac surgery. Cytosorbents also develops DrugSorb-ATR, a device designed to remove certain blood-thinning drugs during cardiac procedures.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.